Outpatient management of fever and neutropenia in adults treated for malignancy

American Society of Clinical Oncology and Infectious Diseases Society of America Clinical practice guideline update

Randy A. Taplitz, Erin B. Kennedy, Eric J. Bow, Jennie Crews, Charise Gleason, Douglas K. Hawley, Amelia A. Langston, Loretta J. Nastoupil, Michelle Rajotte, Kenneth Rolston, Lynne Strasfeld, Christopher R. Flowers

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose To provide an updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline on outpatient management of fever and neutropenia in patients with cancer. Methods ASCO and IDSA convened an Update Expert Panel and conducted a systematic review of relevant studies. The guideline recommendations were based on the review of evidence by the Expert Panel. Results Six new or updated meta-analyses and six new primary studies were added to the updated systematic review. Recommendation Clinical judgment is recommended when determining which patients are candidates for outpatient management, using clinical criteria or a validated tool such as the Multinational Association of Support Care in Cancer risk index. In addition, psychosocial and logistic considerations are outlined within the guideline. The panel continued to endorse consensus recommendations from the previous version of this guideline that patients with febrile neutropenia receive initial doses of empirical antibacterial therapy within 1 hour of triage and be monitored for $ 4 hours before discharge. An oral fluoroquinolone plus amoxicillin/clavulanate (or clindamycin, if penicillin allergic) is recommended as empirical outpatient therapy, unless fluoroquinolone prophylaxis was used before fever developed. Patients who do not defervesce after 2 to 3 days of an initial, empirical, broad-spectrum antibiotic regimen should be re-evaluated and considered as candidates for inpatient treatment.

Original languageEnglish (US)
Pages (from-to)1443-1453
Number of pages11
JournalJournal of Clinical Oncology
Volume36
Issue number14
DOIs
StatePublished - May 10 2018

Fingerprint

Neutropenia
Practice Guidelines
Fever
Outpatients
Guidelines
Fluoroquinolones
Communicable Diseases
Neoplasms
Febrile Neutropenia
Clavulanic Acid
Clindamycin
Triage
Amoxicillin
Penicillins
Meta-Analysis
Inpatients
Consensus
Therapeutics
Joints
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Outpatient management of fever and neutropenia in adults treated for malignancy : American Society of Clinical Oncology and Infectious Diseases Society of America Clinical practice guideline update. / Taplitz, Randy A.; Kennedy, Erin B.; Bow, Eric J.; Crews, Jennie; Gleason, Charise; Hawley, Douglas K.; Langston, Amelia A.; Nastoupil, Loretta J.; Rajotte, Michelle; Rolston, Kenneth; Strasfeld, Lynne; Flowers, Christopher R.

In: Journal of Clinical Oncology, Vol. 36, No. 14, 10.05.2018, p. 1443-1453.

Research output: Contribution to journalArticle

Taplitz, Randy A. ; Kennedy, Erin B. ; Bow, Eric J. ; Crews, Jennie ; Gleason, Charise ; Hawley, Douglas K. ; Langston, Amelia A. ; Nastoupil, Loretta J. ; Rajotte, Michelle ; Rolston, Kenneth ; Strasfeld, Lynne ; Flowers, Christopher R. / Outpatient management of fever and neutropenia in adults treated for malignancy : American Society of Clinical Oncology and Infectious Diseases Society of America Clinical practice guideline update. In: Journal of Clinical Oncology. 2018 ; Vol. 36, No. 14. pp. 1443-1453.
@article{dc50baa2177c4d8d9ed0cc361ae5cb77,
title = "Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical practice guideline update",
abstract = "Purpose To provide an updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline on outpatient management of fever and neutropenia in patients with cancer. Methods ASCO and IDSA convened an Update Expert Panel and conducted a systematic review of relevant studies. The guideline recommendations were based on the review of evidence by the Expert Panel. Results Six new or updated meta-analyses and six new primary studies were added to the updated systematic review. Recommendation Clinical judgment is recommended when determining which patients are candidates for outpatient management, using clinical criteria or a validated tool such as the Multinational Association of Support Care in Cancer risk index. In addition, psychosocial and logistic considerations are outlined within the guideline. The panel continued to endorse consensus recommendations from the previous version of this guideline that patients with febrile neutropenia receive initial doses of empirical antibacterial therapy within 1 hour of triage and be monitored for $ 4 hours before discharge. An oral fluoroquinolone plus amoxicillin/clavulanate (or clindamycin, if penicillin allergic) is recommended as empirical outpatient therapy, unless fluoroquinolone prophylaxis was used before fever developed. Patients who do not defervesce after 2 to 3 days of an initial, empirical, broad-spectrum antibiotic regimen should be re-evaluated and considered as candidates for inpatient treatment.",
author = "Taplitz, {Randy A.} and Kennedy, {Erin B.} and Bow, {Eric J.} and Jennie Crews and Charise Gleason and Hawley, {Douglas K.} and Langston, {Amelia A.} and Nastoupil, {Loretta J.} and Michelle Rajotte and Kenneth Rolston and Lynne Strasfeld and Flowers, {Christopher R.}",
year = "2018",
month = "5",
day = "10",
doi = "10.1200/JCO.2017.77.6211",
language = "English (US)",
volume = "36",
pages = "1443--1453",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "14",

}

TY - JOUR

T1 - Outpatient management of fever and neutropenia in adults treated for malignancy

T2 - American Society of Clinical Oncology and Infectious Diseases Society of America Clinical practice guideline update

AU - Taplitz, Randy A.

AU - Kennedy, Erin B.

AU - Bow, Eric J.

AU - Crews, Jennie

AU - Gleason, Charise

AU - Hawley, Douglas K.

AU - Langston, Amelia A.

AU - Nastoupil, Loretta J.

AU - Rajotte, Michelle

AU - Rolston, Kenneth

AU - Strasfeld, Lynne

AU - Flowers, Christopher R.

PY - 2018/5/10

Y1 - 2018/5/10

N2 - Purpose To provide an updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline on outpatient management of fever and neutropenia in patients with cancer. Methods ASCO and IDSA convened an Update Expert Panel and conducted a systematic review of relevant studies. The guideline recommendations were based on the review of evidence by the Expert Panel. Results Six new or updated meta-analyses and six new primary studies were added to the updated systematic review. Recommendation Clinical judgment is recommended when determining which patients are candidates for outpatient management, using clinical criteria or a validated tool such as the Multinational Association of Support Care in Cancer risk index. In addition, psychosocial and logistic considerations are outlined within the guideline. The panel continued to endorse consensus recommendations from the previous version of this guideline that patients with febrile neutropenia receive initial doses of empirical antibacterial therapy within 1 hour of triage and be monitored for $ 4 hours before discharge. An oral fluoroquinolone plus amoxicillin/clavulanate (or clindamycin, if penicillin allergic) is recommended as empirical outpatient therapy, unless fluoroquinolone prophylaxis was used before fever developed. Patients who do not defervesce after 2 to 3 days of an initial, empirical, broad-spectrum antibiotic regimen should be re-evaluated and considered as candidates for inpatient treatment.

AB - Purpose To provide an updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline on outpatient management of fever and neutropenia in patients with cancer. Methods ASCO and IDSA convened an Update Expert Panel and conducted a systematic review of relevant studies. The guideline recommendations were based on the review of evidence by the Expert Panel. Results Six new or updated meta-analyses and six new primary studies were added to the updated systematic review. Recommendation Clinical judgment is recommended when determining which patients are candidates for outpatient management, using clinical criteria or a validated tool such as the Multinational Association of Support Care in Cancer risk index. In addition, psychosocial and logistic considerations are outlined within the guideline. The panel continued to endorse consensus recommendations from the previous version of this guideline that patients with febrile neutropenia receive initial doses of empirical antibacterial therapy within 1 hour of triage and be monitored for $ 4 hours before discharge. An oral fluoroquinolone plus amoxicillin/clavulanate (or clindamycin, if penicillin allergic) is recommended as empirical outpatient therapy, unless fluoroquinolone prophylaxis was used before fever developed. Patients who do not defervesce after 2 to 3 days of an initial, empirical, broad-spectrum antibiotic regimen should be re-evaluated and considered as candidates for inpatient treatment.

UR - http://www.scopus.com/inward/record.url?scp=85047219014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047219014&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.77.6211

DO - 10.1200/JCO.2017.77.6211

M3 - Article

VL - 36

SP - 1443

EP - 1453

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 14

ER -